Karuna Therapeutics – Trial Evaluating KarXT in Schizophrenia
Dr. Andrew Miller is the Founder and Chief Operating Officer of Karuna Therapeutics and primary inventor of the company’s lead product candidate, KarXT (xanomeline-trospium). Dr. Miller discusses this investigational treatment, which offers a potential new approach to treating schizophrenia and other neuropsychiatric conditions, including psychosis in Alzheimer’s disease, by way of its unique differentiated mechanism of action that does not rely on targeting dopaminergic or serotonergic pathways, as currently available treatments do. If successfully developed and approved, KarXT has the potential to usher in the newest generation of antipsychotics for patients and ultimately change the treatment paradigm as we know it.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Alzheimer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Alzheimer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Alzheimer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Andrew Miller is a Founder and the Chief Operating Officer of Karuna Therapeutics. Dr. Miller is the lead inventor of Karuna’s KarXT platform and served as CEO of Karuna from 2016-2018. He served as a member of Karuna’s board of directors from April 2012 to March 2019. From August 2008 to July 2016, Dr. Miller held several positions at PureTech Health plc, last serving as a Vice President, Venture Partner, and served as Chief Operating Officer of Tal Medical, and the acting Chief Operating Officer of Entrega, Inc. He is currently a member of the board of directors of Entrega, Inc.
Dr. Miller received his bachelor’s degree in Chemical Engineering from the University of Illinois with highest honors, and his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology, and received the MIT Presidential fellow and National Defense Science and Engineering Graduate fellowship awards. In 2016, Dr. Miller was named one of the top 40 innovators under 40 by MedTech Boston.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
